Inge Marie Svane

Inge Marie Svane

Clinical Professor

Member of:

  • Clinical Oncology

ORCID: 0000-0002-9451-6037

Publication year:
All
181 - 190 out of 273Page size: 10
  1. 2020
  2. Published

    CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer

    Friese, C., Harbst, K., Borch, T. H., Westergaard, M. C. W., Pedersen, M., Kverneland, A., Jönsson, G., dqp123, dqp123, Svane, Inge Marie & Met, Özcan, 2020, In: Scientific Reports. 10, 1, 12 p., 3914.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer

    Westergaard, M. C. W., Milne, K., Pedersen, M., Hasselager, T., Olsen, L. R., Anglesio, M. S., Borch, T. H., Kennedy, M., Briggs, G., Ledoux, S., Kreuzinger, C., Decken, I. V. D., Donia, M., Castillo-Tong, D. C., Nelson, B. H. & Svane, Inge Marie, 2020, In: Cancers. 12, 12, 19 p., 3828.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors

    Romanski, N. A., Holmstroem, R. B., Ellebaek, E. & Svane, Inge Marie, 2020, In: European Journal of Cancer. 130, p. 211-218

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma

    Borch, T. H., Andersen, R., Ellebaek, E., Met, Özcan, dqp123, dqp123 & Svane, Inge Marie, 2020, In: Journal for ImmunoTherapy of Cancer. 8, 2, e000668.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Genetic biomarkers in melanoma of the ocular region: What the medical oncologist should know

    Bol, K. F., dqp123, dqp123, Heegaard, Steffen, Kiilgaard, Jens Folke & Svane, Inge Marie, 2020, In: International Journal of Molecular Sciences . 21, 15, p. 1-14 14 p., 5231.

    Research output: Contribution to journal › Review › Research › peer-review

  7. Published

    Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1

    Crowther, M. D., Dolton, G., Legut, M., Caillaud, M. E., Lloyd, A., Attaf, M., Galloway, S. A. E., Rius, C., Farrell, C. P., Szomolay, B., Ager, A., Parker, A. L., Fuller, A., dqp123, dqp123, McCluskey, J., Rossjohn, J., Svane, Inge Marie, Phillips, J. D. & Sewell, A. K., 2020, In: Nature Immunology. 21, 2, p. 178-185 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    Granzyme B Degraded Type IV Collagen Products in Serum Identify Melanoma Patients Responding to Immune Checkpoint Blockade

    Jensen, C., Sinkeviciute, D., Madsen, D. H., Onnerfjord, P., Hansen, M., Schmidt, H., Karsdal, M. A., Svane, Inge Marie & Willumsen, N., 2020, In: Cancers. 12, 10, p. 1-15 2786.

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Improved progression-free long-term survival of a nation-wide patient population with metastatic melanoma

    Soerensen, A. V., Ellebaek, E., Bastholt, L., Schmidt, H., dqp123, dqp123 & Svane, Inge Marie, 2020, In: Cancers. 12, 9, p. 1-11 11 p., 2591.

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes

    Nielsen, M., Krarup-Hansen, Anders, Hovgaard, D., Petersen, Michael Mørk, Loya, Anand Chainsukh, Westergaard, M. C. W., Svane, Inge Marie & Junker, N., 2020, In: Cancer Immunology, Immunotherapy. 69, p. 2179-2191

    Research output: Contribution to journal › Journal article › Research › peer-review

  11. Published

    KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

    Ferrucci, P. F., Di Giacomo, A. M., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Stephens, R., Svane, Inge Marie, Lotem, M., Abu-Amna, M., Gasal, E., Ghori, R., Diede, S. J., Croydon, E. S., Ribas, A., Ascierto, P. A. & KEYNOTE-022 international team, K. I. T., 2020, In: Journal for ImmunoTherapy of Cancer. 8, 2, 8 p., e001806.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1...15 16 17 18 19 20 21 22 ...28 Next

ID: 4054758